However, IDH1 R132 mutation in GBM is also a gain-of-function alteration resulting in hampered production and accelerated consumption of NADPH, which produces the 2-hydroxyglutarate (2-HG) from α-KG [13–15]. This evidence concerns the gene IDH1 and glioblastoma.